Yahoo Web Search

Search results

  1. Ocugen, Inc. (OCGN) is a biopharmaceutical company developing innovative therapies for eye diseases. Learn more about its stock performance, news, history and future prospects at Yahoo Finance ...

    • Stock Forum & Discussion

      Find the latest Ocugen, Inc. (OCGN) stock discussion in...

    • Holders

      Find out the direct holders, institutional holders and...

    • Profile

      See the company profile for Ocugen, Inc. (OCGN) including...

    • Historical Data

      Discover historical prices for OCGN stock on Yahoo Finance....

    • Analysis

      See Ocugen, Inc. (OCGN) stock analyst estimates, including...

    • Statistics

      Find out all the key statistics for Ocugen, Inc. (OCGN),...

    • Financials

      Get the detailed quarterly/annual income statement for...

    • Sustainability

      See Ocugen, Inc. (OCGN) Environment, Social and Governance...

    • Press Releases

      Ocugen to Present at BIO International Convention 2024....

    • SEC Filings

      Find the latest Ocugen, Inc. (OCGN) stock quote, history,...

  2. 2 days ago · OCGN | Complete Ocugen Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

    • 25.00%
    • 16.23%
    • 4.03%
    • 124.35%
  3. Get the latest Ocugen Inc (OCGN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

  4. Get the latest stock price, quote, news and history of Ocugen, Inc. (OCGN), a biotechnology company developing biological products. See the bid, ask, volume, earnings, dividend, and scorecard data of OCGN on Nasdaq.

  5. 5 days ago · A high-level overview of Ocugen, Inc. (OCGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

    • Vanda Pharmaceuticals Inc.
    • Biotechnology
    • 203
    • 363.16M
  6. View the latest Ocugen Inc. (OCGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.

  7. People also ask

  8. Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication. Find the latest Ocugen, Inc. (OCGN) stock quote, history, news and other vital information to help you with your stock trading and investing.

  1. People also search for